Keyword Analysis & Research: theliatinib

clinicaltrials.gov

https://classic.clinicaltrials.gov/ct2/show/NCT02601248

Actual Enrollment : 24 participants Study Type : Interventional (Clinical Trial) Intervention Model: Single Group Assignment

Actual Enrollment : 24 participants

Study Type : Interventional (Clinical Trial)

Intervention Model: Single Group Assignment

DA: 32 PA: 83 MOZ Rank: 91

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584209/

WebAug 1, 2017 · This study demonstrates that theliatinib could potentially benefit EC patients with high EGFR protein expression without mutations or aberrant activities of associated … Author: Yongxin Ren, Jianming Zheng, Shiming Fan, Linfang Wang, Min Cheng, Dongxia Shi, Wei Zhang, Renxiang ... DOI: 10.18632/oncotarget.17243 Publish Year: 2017 Publication: Oncotarget. 2017 Aug 1; 8(31): 50832-50844.

Author: Yongxin Ren, Jianming Zheng, Shiming Fan, Linfang Wang, Min Cheng, Dongxia Shi, Wei Zhang, Renxiang ...

DOI: 10.18632/oncotarget.17243

Publish Year: 2017

Publication: Oncotarget. 2017 Aug 1; 8(31): 50832-50844.

DA: 31 PA: 12 MOZ Rank: 57

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584209/

DA: 6 PA: 91 MOZ Rank: 40

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836115/

WebSep 26, 2019 · The PD1 inhibitor nivolumab, which was found in one study to outperform chemotherapy irrespective of PDL1 status, has yet to secure FDA approval. In terms of … Author: Adam Barsouk, Prashanth Rawla, Andreas V Hadjinicolaou, John Sukumar Aluru, Alexander Barsouk DOI: 10.3390/medsci7100100 Publish Year: 2019 Publication: Med Sci (Basel). 2019 Oct; 7(10): 100.

Author: Adam Barsouk, Prashanth Rawla, Andreas V Hadjinicolaou, John Sukumar Aluru, Alexander Barsouk

DOI: 10.3390/medsci7100100

Publish Year: 2019

Publication: Med Sci (Basel). 2019 Oct; 7(10): 100.

DA: 54 PA: 68 MOZ Rank: 4

cancer-research-network.com

https://www.cancer-research-network.com/2023/05/11/theliatinib-tartrate-is-an-orally-active-egfr-inhibitor-for-esophageal-cancer-research/

WebMay 11, 2023 · Here, we’ll introduce Theliatinib tartrate, an orally effective EGFR inhibitor against esophageal cancer. Theliatinib tartrate potently, and selectively inhibits EGFR …

DA: 33 PA: 50 MOZ Rank: 94

nih.gov

https://pubmed.ncbi.nlm.nih.gov/28881608/

WebApr 19, 2017 · This study demonstrates that theliatinib could potentially benefit EC patients with high EGFR protein expression without mutations or aberrant activities of associated … Author: Yongxin Ren, Jianming Zheng, Shiming Fan, Linfang Wang, Min Cheng, Dongxia Shi, Wei Zhang, Renxiang ... Publish Year: 2017

Author: Yongxin Ren, Jianming Zheng, Shiming Fan, Linfang Wang, Min Cheng, Dongxia Shi, Wei Zhang, Renxiang ...

Publish Year: 2017

DA: 78 PA: 11 MOZ Rank: 100

hutch-med.com

https://www.hutch-med.com/wp-content/uploads/2017/09/pre170928-csco-309.pdf

WebNovel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial. 2014-309-00CH1. Presenter: Jifang Gong, Beijing Cancer Hospital. Lin Shen1, Li Zhang2, …

DA: 12 PA: 71 MOZ Rank: 94

oncotarget.com

https://www.oncotarget.com/article/17243/

WebApr 19, 2017 · Theliatinib exhibited strong antitumor activity in PDECX models with high EGFR expression, including remarkable tumor regression in two PDECX models with …

DA: 68 PA: 36 MOZ Rank: 2

semanticscholar.org

https://www.semanticscholar.org/paper/Anti-tumor-efficacy-of-theliatinib-in-esophageal-Ren-Zheng/7f46ff436066cb7c642175b2668a96db7eb91d85

WebApr 19, 2017 · Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and …

DA: 99 PA: 78 MOZ Rank: 99